bombesin: the satiety and cancer-research neuropeptide explained

bombesin is a 14-amino-acid neuropeptide first isolated from the skin of the European fire-bellied toad in 1971. its mammalian homologs are gastrin-releasing peptide (GRP) and neuromedin B (NMB). the family signals through three G-protein-coupled receptors (GRPR, NMBR, BRS3) that regulate satiety, gut motility, thermoregulation, and tumor growth. it is not approved as a medicine but is an active scaffold in cancer-imaging research.

what is bombesin?

bombesin is a tetradecapeptide originally purified by Vittorio Erspamer's group from the skin of Bombina bombina, the European fire-bellied toad. its identification was part of a broader era of amphibian-skin peptide discovery that revealed mammalian neuropeptide families that had been hiding in plain sight.

bombesin itself is an amphibian molecule, but the family it defined turned out to be much wider. in mammals the two endogenous "bombesin-like" peptides are gastrin-releasing peptide (GRP), a 27-residue peptide named for its ability to release the gut hormone gastrin, and neuromedin B (NMB), a 10-residue peptide. both share bombesin's C-terminal sequence, which is the part that docks into the receptors, and both are produced and released by neurons and enteroendocrine cells [1]. when "bombesin" appears in a modern paper, the authors often mean the broader family signaling, not the literal frog peptide.

how does it signal?

bombesin and its mammalian homologs signal through three closely related G-protein-coupled receptors. GRPR (BB2) is the main GRP receptor and the one most often associated with bombesin's satiety, gut, and cancer-related effects. NMBR (BB1) is the neuromedin B receptor. BRS3 (BB3) is a third receptor with no confirmed endogenous ligand, studied as an orphan metabolic target.

all three receptors are Gq-coupled GPCRs. when bombesin or GRP engages GRPR, the receptor activates phospholipase C, which raises intracellular calcium and activates protein kinase C. in neurons this drives action-potential firing; in smooth muscle it drives contraction; and in epithelial cells it drives proliferation, which is the link to the cancer-imaging program [2].

the central effects are best characterized for GRPR. GRPR-expressing neurons in the hypothalamus and brainstem modulate meal termination, gastric emptying, and thermoregulation, and GRPR is also expressed in the spinal cord where it has been mapped onto itch-specific pathways. NMBR shows up more strongly in thermoregulation and anxiety circuits. BRS3 is the orphan: no endogenous ligand has been confirmed, but BRS3-knockout mice develop obesity and hypertension, which is why pharmaceutical groups have screened BRS3 agonists as candidate anti-obesity tools.

what does the evidence show in humans?

the strongest human signal for bombesin is on short-term satiety. controlled intravenous bombesin infusion in healthy volunteers reduced food intake at the next meal in early Reading and Yale studies. those findings established bombesin as a satiety peptide but did not translate into an approved drug program.

the foundational human satiety work was published by Muurahainen, Kissileff, and colleagues in the late 1980s, using IV bombesin infusion during a test meal in healthy volunteers and measuring intake [3]. a parallel series by Gutzwiller and Beglinger in the 1990s extended the work to lean and obese subjects and to longer infusion paradigms [4]. across these studies, bombesin reproducibly reduced ad libitum meal size and reported hunger, which is the kind of pharmacology that motivated the original "bombesin for obesity" interest.

none of that translated into a marketed drug. bombesin's pharmacokinetics are poor (short circulating half-life, peptide clearance), the side-effect profile included gut symptoms and blood-pressure shifts, and once the GLP-1 family arrived with sermaglutide-class molecules that produced multi-percent body-weight changes, the bombesin axis lost its commercial logic. appetite research still treats bombesin as a teaching example of a satiety hormone, but the clinical pipeline moved elsewhere.

a related area is itch. Sun and Chen's group at Washington University identified GRPR as the spinal-cord receptor mediating histamine-independent itch in mice, which reframed GRPR as a target for chronic itch syndromes [5]. that line of work is still preclinical.

bombesin in cancer imaging

the most active modern use of bombesin is as a radiopharmaceutical scaffold. GRPR is overexpressed in a majority of prostate cancers and in many breast and small-cell lung cancers, which makes it a tumor-localization beacon. labeled bombesin analogs let imaging scans light up GRPR-positive tumors and, in theranostic versions, deliver a therapeutic radionuclide to them.

the typical scaffold is a short bombesin-derived peptide (often a GRPR antagonist for better receptor residence time) conjugated to a chelator that holds a metallic radionuclide. gallium-68 (Ga-68) labeled analogs are used for PET imaging; copper-64 has also been studied. for therapeutic delivery, the same peptide is labeled with lutetium-177 (Lu-177) or actinium-225 (Ac-225) to deliver targeted radiation to GRPR-positive cells [6]. the family of compounds includes RM2, NeoBOMB1, and Sarabesin-3 (SB3), each with different chelator-and-linker chemistry.

clinical pilot studies through 2024 reported encouraging tumor uptake and dosimetry in prostate-cancer patients, particularly in PSMA-negative or PSMA-low disease where existing PSMA imaging falls short [7]. the field is still pre-approval, but bombesin radiopharmaceuticals are the most likely route by which the bombesin family reaches the clinic.

where it fits in the broader peptide landscape

bombesin sits with the other historical "satiety peptides" — CCK, GLP-1, PYY — as part of the gut-brain axis that signals meal termination. it is the more research-only end of that family, eclipsed clinically by GLP-1, but increasingly important as a tumor-imaging target.

the natural comparison is cholecystokinin (CCK), the other classical satiety peptide. CCK and bombesin both reduce meal size on acute infusion, both work through Gq-coupled receptors, and both suffered the same fate of being eclipsed clinically by the GLP-1 family. the comparison with the GLP-1 axis (including semaglutide and tirzepatide) is covered in our GLP-1 comparison blog.

on the central side, bombesin sits in the same broad category as neuropeptide Y as a peptide that the brain uses to set the balance between hunger and satiety. NPY drives the hunger side, bombesin pushes the satiety side, and the net of those signals determines where meal termination lands. the relevance of bombesin today is more as a teaching example of how that balance works than as a candidate drug.

safety, status, and honest framing

there is no FDA-approved bombesin or bombesin-family agonist for any indication, satiety or otherwise. radiolabeled bombesin analogs are in clinical research as imaging and theranostic agents but are not yet marketed. anything sold as bombesin to consumers is outside any regulatory pathway.

the side-effect profile in the human infusion literature includes nausea, abdominal cramping, transient hypertension, and reflex bradycardia, all consistent with GRPR engagement in the gut and brainstem. chronic safety data in non-radiopharmaceutical contexts is essentially absent because no chronic-dose program has run. the radiopharmaceutical doses are tiny by mass and short by exposure, so their safety profile is dominated by the radionuclide, not the peptide itself.

honest framing: bombesin is a textbook neuropeptide with a fifty-year research arc, a clear receptor family, and a real but narrow modern utility in cancer imaging. it is not a consumer peptide and not a satiety drug. anyone seeing bombesin marketed as a weight-loss product is looking at a category error.